Your browser doesn't support javascript.
loading
Reduced COVID-19 hospitalizations among New York City residents following age-based SARS-CoV-2 vaccine eligibility: Evidence from a regression discontinuity design.
Greene, Sharon K; Levin-Rector, Alison; McGibbon, Emily; Baumgartner, Jennifer; Devinney, Katelynn; Ternier, Alexandra; Sell, Jessica; Kahn, Rebecca; Kishore, Nishant.
Afiliação
  • Greene SK; Bureau of Communicable Disease, New York City Department of Health and Mental Hygiene, Long Island City, NY, USA.
  • Levin-Rector A; Bureau of Communicable Disease, New York City Department of Health and Mental Hygiene, Long Island City, NY, USA.
  • McGibbon E; Bureau of Communicable Disease, New York City Department of Health and Mental Hygiene, Long Island City, NY, USA.
  • Baumgartner J; Bureau of Communicable Disease, New York City Department of Health and Mental Hygiene, Long Island City, NY, USA.
  • Devinney K; Bureau of Communicable Disease, New York City Department of Health and Mental Hygiene, Long Island City, NY, USA.
  • Ternier A; Bureau of Immunization, New York City Department of Health and Mental Hygiene, Long Island City, NY, USA.
  • Sell J; Bureau of Communicable Disease, New York City Department of Health and Mental Hygiene, Long Island City, NY, USA.
  • Kahn R; Center for Communicable Disease Dynamics, Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
  • Kishore N; Center for Communicable Disease Dynamics, Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Vaccine X ; 10: 100134, 2022 Apr.
Article em En | MEDLINE | ID: mdl-34961848
ABSTRACT

BACKGROUND:

In clinical trials, several SARS-CoV-2 vaccines were shown to reduce risk of severe COVID-19 illness. Local, population-level, real-world evidence of vaccine effectiveness is accumulating. We assessed vaccine effectiveness for community-dwelling New York City (NYC) residents using a quasi-experimental, regression discontinuity design, leveraging a period (January 12-March 9, 2021) when ≥ 65-year-olds were vaccine-eligible but younger persons, excluding essential workers, were not.

METHODS:

We constructed segmented, negative binomial regression models of age-specific COVID-19 hospitalization rates among 45-84-year-old NYC residents during a post-vaccination program implementation period (February 21-April 17, 2021), with a discontinuity at age 65 years. The relationship between age and hospitalization rates in an unvaccinated population was incorporated using a pre-implementation period (December 20, 2020-February 13, 2021). We calculated the rate ratio (RR) and 95% confidence interval (CI) for the interaction between implementation period (pre or post) and age-based eligibility (45-64 or 65-84 years). Analyses were stratified by race/ethnicity and borough of residence. Similar analyses were conducted for COVID-19 deaths.

RESULTS:

Hospitalization rates among 65-84-year-olds decreased from pre- to post-implementation periods (RR 0.85, 95% CI 0.74-0.97), controlling for trends among 45-64-year-olds. Accordingly, an estimated 721 (95% CI 126-1,241) hospitalizations were averted. Residents just above the eligibility threshold (65-66-year-olds) had lower hospitalization rates than those below (63-64-year-olds). Racial/ethnic groups and boroughs with higher vaccine coverage generally experienced greater reductions in RR point estimates. Uncertainty was greater for the decrease in COVID-19 death rates (RR 0.85, 95% CI 0.66-1.10).

CONCLUSION:

The vaccination program in NYC reduced COVID-19 hospitalizations among the initially age-eligible ≥ 65-year-old population by approximately 15% in the first eight weeks. The real-world evidence of vaccine effectiveness makes it more imperative to improve vaccine access and uptake to reduce inequities in COVID-19 outcomes.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Vaccine X Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Vaccine X Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos